AlloCure, Inc.

Industry

  • Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy
See more in Biomedtracker

Latest on AlloCure, Inc.

Scrip

Recent Financings Of Private Companies, May 2012

 
• By Deanna Kamienski, Beth Allan, Andrea Mancini, Amanda Micklus, Maureen Riordan, and Theresa Surprenant

IN VITRO DIAGNOSTICS Abingdon Health Ltd. Abingdon Health brings in £3mm through an early-stage venture round Abingdon Health Ltd. (diagnostics) has raised £3mm ($4.8mm) through an early-stage

Scrip

AlloCure raises $25mn to take lead stem cell therapy into Phase II

 
• By Mandy Jackson

AlloCure has raised $25 million in a Series B financing round involving one new investor, Lundbeckfond Ventures, which becomes the second Danish corporate venture fund to invest in the Burlington, Mas

In Vivo

Biopharma Quarterly Deal Statistics, Q2 2012

Financings Seventy-nine financings raised $2.7 billion during the second quarter of 2012, down from the previous quarter ($3.7 billion from 101 deals) and Q2 last year ($6.3 billion from 89 transactio

Scrip

AlloCure Inc.

 
• By Deborah Erickson

Seeking a cell-based therapy for kidney injury 25 Corporate Drive Suite 360 Burlington, MA 01803 Phone: (781) 425-5380 Web Site: www.allocure.com Contact: Robert Brenner, MD, President & CEO Industry